Key result
Differences in amiodarone doses between treatment groups may confound conclusions regarding ventricular tachycardia recurrence in patients with Chagas cardiomyopathy.
Why the study?
Does the dose of amiodarone confound the comparison between ablation and medical therapy for preventing VT recurrence in Chagas cardiomyopathy?
Does the dose of amiodarone confound the comparison between ablation and medical therapy for preventing VT recurrence in Chagas cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Highlights that inadequate or variable amiodarone dosing might confound the apparent superiority of ablation over medical therapy for ventricular tachycardia in Chagas cardiomyopathy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Veloso et al. (2026) conducted a letter in Chagas cardiomyopathy with ventricular tachycardia. Amiodarone was evaluated. Differences in amiodarone doses between treatment groups may confound conclusions regarding ventricular tachycardia recurrence in patients with Chagas cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: